ServiceNow is riding a wave of AI sales for enterprise customers
By Jon Swartz
ServiceNow Inc. is reaping the benefits nearly a year after its push into generative artificial intelligence.
The software company's stock (NOW) fell 5% in after-hours trading Wednesday following quarterly results propelled by AI sales that topped analysts' revenue and earnings estimates.
"We've become the AI platform for business transformation, for running a company on one platform," ServiceNow Chief Executive Bill McDermott said in an interview. "It's fueling performance for each of our key businesses and driving real, tangible value for customers like Microsoft Corp. (MSFT) and IBM Corp. (IBM). The old rules are getting really tired. This is a rethink-everything moment."
McDermott added: "Deals over $5 million are up 100%, and deals over $10 million are up 300% [year over year]."
ServiceNow posted fiscal first-quarter net income of $347 million, or $1.67 a share, compared with net income of $150 million, or 73 cents a share, in the same quarter a year ago. Adjusted earnings were $3.45 a share.
Revenue climbed 24% to $2.6 billion from the same quarter a year ago.
Analysts surveyed by FactSet had expected, on average, net earnings of $3.15 a share on revenue of $2.59 billion.
ServiceNow provided second-quarter subscription-revenue guidance of $2.525 billion to $2.53 billion, while FactSet analysts are forecasting $2.61 billion.
Shares of ServiceNow have catapulted 63% over the past year, but the increases have slowed in 2024. The S&P 500 index SPX is up 25% over the past 12 months.
In recent days, analysts have been ebullient about the company's stock prospects. Last week, Citigroup raised its price target to $906 from $896.
Paul Marino, chief revenue officer at GraniteShares, argues ServiceNow is "quietly making huge strides in automating the workplace and enhancing productivity through AI and [robotic process automation]."
"This upcoming earnings report will show how ServiceNow is setting a new standard for what technology can do for businesses," Marino said in an email.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-24-24 1616ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing